Michael Owen
Direktor/Vorstandsmitglied bei SAREUM HOLDINGS PLC
Vermögen: 667 906 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael Elliot Hunt | M | 62 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 23 Jahre |
Tony Gardiner | M | 53 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | 8 Jahre |
Simon Cartmell | M | 64 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 10 Jahre |
Olav Hellebø | M | 59 |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | 10 Jahre |
Amit Chunilal Nathwani | M | 64 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 5 Jahre |
John Reader | M | 56 | 21 Jahre | |
Alf Gunnar Martin Nicklasson | M | 69 | 9 Jahre | |
Frank S. Walsh | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 13 Jahre |
Clive Birch | M | 70 | 6 Jahre | |
Timothy Mitchell | M | 63 | 21 Jahre | |
Corey Goodman | M | 72 |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 13 Jahre |
Eliot Forster | M | 58 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | 6 Jahre |
J. Lynn Rutkowski | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | - |
Jeffrey Berkowitz | M | 58 | 5 Jahre | |
Bengt Westermark | M | 79 |
European Molecular Biology Organization
| - |
Peter Goodfellow | M | 72 |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | 9 Jahre |
Barbara Staehelin | F | 61 | 3 Jahre | |
Martin Walton | M | 61 | 2 Jahre | |
Bernadette Connaughton | F | 65 | 5 Jahre | |
Leonard Kruimer | M | 66 | 5 Jahre | |
Nilesh Modi | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Trevor Nicholls | M | 67 |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | - |
Ivan M. Møller | M | 52 | 6 Jahre | |
Paul Fry | M | 58 | 4 Jahre | |
Kirsten Drejer | M | 68 | 6 Jahre | |
Alastair Smith | M | - |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | - |
Anneline Nansen | F | 55 | 3 Jahre | |
Steve Moore | M | - |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | 12 Jahre |
Hermona Soreq | M | - |
European Molecular Biology Organization
| - |
Christina Sonnenborg Bredal | F | 39 | 4 Jahre | |
Brian Silver | M | 55 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Sally Jackson | F | - | 23 Jahre | |
Seung Suh Hong | M | 66 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 3 Jahre |
Fulvio Mavilio | M | - |
European Molecular Biology Organization
| - |
Henriette Wennicke | F | - | 2 Jahre | |
Antonio Lanzavecchia | M | 73 |
European Molecular Biology Organization
| - |
Samit Govindji Hathi | M | 57 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Bharat Kumar Hirji Thakrar | M | 67 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Dirk Heinz | M | - |
European Molecular Biology Organization
| 15 Jahre |
Karen Vousden | M | 66 |
European Molecular Biology Organization
| - |
Luke O'Neill | M | 60 |
European Molecular Biology Organization
| 19 Jahre |
Paul Schulze Lefert | M | - |
European Molecular Biology Organization
| - |
Rudy Dekeyser | M | 63 |
The European Molecular Biology Laboratory
| - |
David Glover | M | - |
European Molecular Biology Organization
| - |
Hans Lennart Rudolf Wigzell | M | 86 |
European Molecular Biology Organization
| - |
Patrick Baeuerle | M | 66 |
European Molecular Biology Organization
| - |
Erkki Ruoslahti | M | 84 |
European Molecular Biology Organization
| - |
David M. Kendall | M | 62 | 2 Jahre | |
Daniel L. Farkas | M | 70 |
European Molecular Biology Organization
| - |
Alan R. Williamson | M | 87 |
The European Molecular Biology Laboratory
| - |
Robert Kamen | M | 79 |
European Molecular Biology Organization
| 48 Jahre |
Yigong Shi | M | 57 |
European Molecular Biology Organization
| - |
Raymond Kaempfer | M | - |
European Molecular Biology Organization
| - |
Peter Ratcliffe | M | 69 |
European Molecular Biology Organization
| - |
Joe D. Lewis | M | 57 |
The European Molecular Biology Laboratory
| - |
Laurence Harris Pearl | M | - |
European Molecular Biology Organization
| - |
Spyridon Artavanis-Tsakonas | M | 77 |
European Molecular Biology Organization
| - |
Ashok Venkitaraman | M | - |
European Molecular Biology Organization
| - |
Peter Andersen | M | 67 |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | - |
Victoria Whyte | F | - | 15 Jahre | |
Stephen Philip Jackson | M | - |
European Molecular Biology Organization
| 27 Jahre |
Anita Kidgell | F | - | 16 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
John Hawkins | M | 58 | 10 Jahre | |
Catherine Isted | F | - | 2 Jahre | |
Timothy Sykes | M | 55 | 9 Jahre | |
Timothy Corn | M | 73 | 10 Jahre | |
John Hyttel | M | 78 | 15 Jahre | |
John Berriman | M | 76 | 9 Jahre | |
Moncef Slaoui | M | 64 | 11 Jahre | |
Patrick J. T. Vallance | M | 64 | - | |
Rosemary Crane | F | 64 | 4 Jahre | |
Gregory Winter | M | 73 |
University of Cambridge
| 7 Jahre |
Hanne Leth Hillman | F | 59 | 5 Jahre | |
Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 Jahre |
Mats Blom | M | 59 | 9 Jahre | |
Mads Vindahl Kronborg | M | - | - | |
Alain Munoz | M | 75 | 17 Jahre | |
Roy Anderson | M | 76 | 11 Jahre | |
Rasmus Just | M | 48 | 14 Jahre | |
Daniel Podolsky | M | 70 | 10 Jahre | |
Belita S. Ong | F | - |
University of Cambridge
| 4 Jahre |
Stephanie Burns | M | 69 | 9 Jahre | |
Christopher Viehbacher | M | 64 | 20 Jahre | |
Richard Sykes | M | 79 | 7 Jahre | |
Jean-Pierre Garnier | M | 75 | 8 Jahre | |
H. Culp | M | 60 | 9 Jahre | |
Deryck Charles Maughan | M | 76 | 12 Jahre | |
Ian Maurice Gray Prosser | M | 81 | 9 Jahre | |
Robert Wilson | M | 81 | 11 Jahre | |
Christopher Gent | M | 75 | 11 Jahre | |
John David Coombe | M | 79 | 5 Jahre | |
Peter Traber | M | 69 | 3 Jahre | |
Michèle Barzach | M | - | 7 Jahre | |
James Murdoch | M | 51 | 3 Jahre | |
Crispin Davis | M | 75 | 10 Jahre | |
Tom de Swaan | M | 78 | 9 Jahre | |
Bahman Yamini | M | - |
University of Cambridge
| 5 Jahre |
Alex Howarth | M | 55 | 10 Jahre | |
Gareth Beynon | M | - |
University of Cambridge
| 6 Jahre |
Eva Steiness | M | 83 | 19 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 53 | 53,00% |
Deutschland | 24 | 24,00% |
Dänemark | 18 | 18,00% |
Vereinigte Staaten | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Owen
- Persönliches Netzwerk